Αποτελέσματα Αναζήτησης
3 Ιαν 2020 · Learning Objectives: On completion of this article, you should be able to (1) recognize the risk of colorectal cancer in the elderly, (2) determine when to stop screening for colorectal cancer in the elderly, and (3) explain the difference in the risks and benefits of the available colorectal cancer screening modalities.
- Acquired Beauty Mark
An otherwise healthy young female patient presented with a...
- Acquired Beauty Mark
20 Ιουλ 2020 · The study comes a month after research published in the Annals of Internal Medicine found that having a negative screening colonoscopy (i.e., one that didn’t find anything of concern) was linked to a lower risk of both developing colorectal cancer and death for up to 17.4 years.
Colonoscopy in very elderly patients (over 80 years of age) carries a greater risk of complications, adverse events and morbidity than in younger patients, and is associated with lower completion rates and higher chance of poor bowel preparation.
Colonoscopy-associated risks can be mitigated in older patients by conducting thorough medication review, coordinating with the prescribing provider, educating the patient about bowel preparation, adjusting sedation, and using endoscopic techniques that minimize perforation and bleed risk.
2 Ιουν 2018 · This paper will examine the role of colonoscopy in very elderly patients for the non-endoscopist, in addition to exploring the particular risks in this population, the yield of colonoscopy, potential alternative investigations and a suggested pragmatic approach for the general physician.
3 Οκτ 2024 · Key Takeaways. Doctors only recommend colonoscopies for seniors aged 76 to 85 on a case-by-case basis, due to the higher risks involved for seniors. If a colonoscopy is needed, seniors should properly prep for the procedure to ensure a safe and successful screening.
Screening endoscopy after 75 years of age was associated with reduced risk of CRC incidence (multivariable hazard ratio [HR], 0.61; 95% CI, 0.51-0.74) and CRC-related mortality (HR, 0.60; 95% CI, 0.46-0.78), regardless of screening history.
